Key result
Inhibition of endogenous nitric oxide synthase with L-NMMA during adenylyl cyclase stimulation further increased Emax by 26% and reduced PVA by 9% without altering mechanical efficiency.
Why the study?
Does cardiac NOS inhibition with L-NMMA augment the contractile response to adenylyl cyclase stimulation with colforsin daropate in patients with idiopathic dilated cardiomyopathy?
Population
13 patients with heart failure due to idiopathic dilated cardiomyopathy, normal sinus rhythm, NYHA…
Comparison
Concurrent infusion of colforsin daropate and… vs Baseline and colforsin daropate infusion alone.
Design
Case_series
Follow-up
Acute (during cardiac catheterization)
Authors
Loading...
May augment adenylyl cyclase inotropic response in dilated cardiomyopathy without efficiency loss; hypothesis-generating, requires prospective trials before any clinical consideration.
Does cardiac NOS inhibition with L-NMMA augment the contractile response to adenylyl cyclase stimulation with colforsin daropate in patients with idiopathic dilated cardiomyopathy?
Inhibition of endogenous nitric oxide synthase with L-NMMA augments the positive inotropic response to adenylyl cyclase stimulation without worsening myocardial mechanical efficiency in patients with idiopathic dilated cardiomyopathy.
Ohta et al. (2007) studied Heart failure due to idiopathic cardiomyopathy (n=13). NG-monomethyl-L-arginine (L-NMMA) with colforsin daropate vs. Colforsin daropate alone was evaluated on Left ventricular hemodynamics and mechanoenergetics (Emax, EW, PVA, MVO2, mechanical efficiency). Inhibition of endogenous nitric oxide synthase with L-NMMA during adenylyl cyclase stimulation further increased Emax by 26% and reduced PVA by 9% without altering mechanical efficiency.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: